"The CCMC license agreement is an endorsement of both OGT's expertise in gene-focused arrays and our commitment to developing accurate solutions for early cancer detection and accurate disease characterization," Dr. Mike Evans, CEO at OGT, said in a press release. "We are proud to be able to contribute to the good work undertaken by the CCMC to further cancer research through increasing access to more comprehensive, accurately interpreted molecular information."